ONC BeiGene Ltd.

  1. Stocks
  2. Healthcare
  3. NASDAQ: ONC

Price (delayed)

$280.23

Market cap

$31.19B

P/E Ratio

778.42

Dividend/share

N/A

EPS

$0.36

Enterprise value

$28.45B

?
Relative Growth: Rel. Growth: 85
Relative Strength: Rel. Strength: 34
Relative Valuation: Rel. Valuation: 17
Relative Profitability: Rel. Profitability: 94

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) ...

Highlights
BeiGene's quick ratio has surged by 94% YoY and by 7% QoQ
The company's EPS has surged by 80% QoQ
BeiGene's debt has soared by 106% YoY and by 2.7% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.beigene.com
Peers: OPK ORGO

Key stats

What are the main financial stats of ONC

ONC stock price

How has the BeiGene stock price performed over time
Intraday
0.44%
1 week
-3.56%
1 month
-5.69%
1 year
8.5%
YTD
-7.76%
QTD
-5.64%

Financial performance

How have BeiGene's revenue and profit performed over time
Revenue
$5.74B
Gross profit
$5.07B
Operating income
$685.94M
Net income
$513.02M
Gross margin
88.3%
Net margin
8.9%
BeiGene's net margin has soared by 195% YoY and by 65% from the previous quarter
The net income has surged by 79% since the previous quarter
BeiGene's operating income has surged by 53% QoQ
The company's gross profit rose by 43% YoY and by 8% QoQ

Price vs fundamentals

How does ONC's price correlate with its fundamentals

Growth

What is BeiGene's growth rate over time

Valuation

What is BeiGene stock price valuation
P/E
778.42
P/B
6.54
P/S
5.42
EV/EBIT
37.82
EV/EBITDA
31.53
EV/Sales
4.96
The company's EPS has surged by 80% QoQ
The equity has grown by 36% YoY and by 9% from the previous quarter
The price to book (P/B) is 15% lower than the last 4 quarters average of 7.7 but 9% higher than the 5-year quarterly average of 6.0
ONC's price to sales (P/S) is 56% lower than its 5-year quarterly average of 12.4 and 14% lower than its last 4 quarters average of 6.3
The revenue has grown by 37% YoY and by 7% from the previous quarter

Efficiency

How efficient is BeiGene business performance
The company's return on assets has surged by 200% YoY and by 63% QoQ
ONC's return on equity has surged by 66% since the previous quarter
The company's return on sales rose by 47% QoQ
BeiGene's ROIC has increased by 38% from the previous quarter

Dividends

What is ONC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ONC.

Financial health

How did BeiGene financials performed over time
The total assets is 126% greater than the total liabilities
BeiGene's quick ratio has surged by 94% YoY and by 7% QoQ
The current ratio has soared by 86% year-on-year and by 7% since the previous quarter
BeiGene's debt is 57% less than its equity
BeiGene's debt has soared by 106% YoY and by 2.7% from the previous quarter
BeiGene's debt to equity has surged by 54% YoY but it has decreased by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.